Earnings call transcript: Best Agrolife lifts profit in Q2 2026 as revenue falls

Best Agrolife’s Q2 FY2027 revenue fell 21% year over year to INR 407 crore, but EBITDA rose 30% to INR 101 crore and profit after tax climbed 48% to INR 57 crore. Gross margin expanded 12 percentage points to 45%, with patented products increasing to 60% of revenue as the company reduced generic sales; management attributed weaker revenue to challenging kharif conditions and the portfolio shift. Management expects profitability to keep improving but cautioned that H2 revenue may not be substantially higher year over year. Shares were reported up 2.79% to $14.37.

Analysis

Best Agrolife — treat this as an earnings-quality test, not yet a growth inflection. The key asymmetry is that profit improvement appears to come from both portfolio pruning and cost restraint; neither proves that patented products can replace lost generic volume at scale. The reported rise in patented-product share is partly a mix effect from generic sales falling, so verify absolute patented-product revenue, repeat orders and contribution after channel economics before underwriting a durable re-rating. B2B supply relationships with UPL’s SWAL subsidiary and Adama offer potential reach, but may also leave Best Agrolife with less control over end-market demand and the value captured per sale.

Near term (1–3 months), the main catalyst and risk is whether sales-return provisions prove conservative or are released into reported earnings. The 95% return collection claim is encouraging, but collection does not independently establish the final credit-note or inventory impact. Separately, elevated plant inventory and working-capital borrowing make cash conversion more important than PAT; February–March inventory normalization is a specific execution test. Weather and sowing recovery could help volumes, but should not be confused with evidence of share gains.

Over 6–18 months, successful launches, registrations and export conversion could make the mix shift structurally valuable. Patent applications and a Brazil subsidiary are options, not current earnings proof. The contrarian risk is that investors extrapolate margin expansion while accepting weak revenue: if patented growth does not offset planned generic exits, fixed costs and working capital can pressure returns despite high reported margins. No valuation, liquidity or forecast data are supplied, so conviction for an outright position is limited.

Key Decisions for Investors

• Do not chase the immediate earnings reaction. Keep Best Agrolife on a catalyst watch until the next results clarify absolute patented-product sales, revenue trajectory and cash conversion.
• Conditional long only on evidence that patented-product revenue is growing in absolute terms and margins hold without material sales-return provision releases. Falsify the thesis if revenue remains weak while gross/EBITDA margins retreat or inventory fails to normalize around February–March.
• Prioritize balance-sheet diligence over PAT: track inventory, receivables, borrowings and operating cash flow alongside the company’s stated plant-inventory reduction. Any further working-capital borrowing without improving cash conversion weakens the equity case.
• Treat international registrations, the Brazil subsidiary and partner channels as longer-dated optionality; do not capitalize them as near-term earnings until repeat shipments and realized economics are disclosed.